OncoCyte Corp (OCX)
2.75
+0.08
(+3.00%)
USD |
NASDAQ |
Nov 22, 14:09
OncoCyte Revenue (Quarterly): 0.115M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.115M |
| June 30, 2024 | 0.104M |
| March 31, 2024 | 0.176M |
| December 31, 2023 | 0.314M |
| September 30, 2023 | 0.429M |
| June 30, 2023 | 0.463M |
| March 31, 2023 | 0.297M |
| December 31, 2022 | 0.274M |
| September 30, 2022 | 0.067M |
| June 30, 2022 | 0.237M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.38M |
| December 31, 2021 | -1.94M |
| September 30, 2021 | 0.984M |
| June 30, 2021 | 2.03M |
| March 31, 2021 | 1.124M |
| December 31, 2020 | 0.503M |
| September 30, 2020 | 0.555M |
| June 30, 2020 | 0.143M |
| March 31, 2020 | 0.016M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-1.94M
Minimum
Dec 2021
2.03M
Maximum
Jun 2021
0.3301M
Average
0.297M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| Fonar Corp | 24.96M |
| XWELL Inc | 8.422M |
| ProPhase Labs Inc | 3.146M |
| Applied DNA Sciences Inc | 0.7975M |
| Veracyte Inc | 115.86M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -13.49M |
| Total Expenses (Quarterly) | 6.49M |
| EPS Diluted (Quarterly) | -0.98 |
| Enterprise Value | 41.59M |
| Gross Profit Margin (Quarterly) | 43.48% |
| Profit Margin (Quarterly) | -11.73K% |
| Earnings Yield | -165.1% |
| Normalized Earnings Yield | -84.88 |